The effects of antihypertensive therapy on haemostatic parameters

被引:24
作者
Ganotakis, ES
Papadakis, JA
Vrentzos, GE
Mikhailidis, DP
机构
[1] Royal Free Hosp, Dept Clin Biochem, Vasc Dis Prevent Clin, London NW3 2QG, England
[2] Univ Crete, Dept Internal Med, Iraklion, Greece
[3] UCL, Sch Med, London W1N 8AA, England
关键词
angiotensin; antihypertensive drugs; coagulation; endothelium; fibrinolysis; haemostasis; nitric oxide; platelets;
D O I
10.2174/1381612033453839
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There is extensive trial-based evidence showing that antihypertensive drugs reduce the risk of vascular events (e.g. stroke and myocardial infarction) as well as target organ damage (e.g. left ventricular hypertrophy and microalbuminuria). However, some of these benefits appear to be, at least partially, independent of the extent of blood pressure (BP) lowering. It is also evident that in certain clinical situations some antihypertensive drugs are more effective than others. In this review we discuss the effects of antihypertensive drugs on the endothelium, platelets, fibrinolysis and coagulation. These properties may account for the observed BP-independent actions. Antihypertensive drugs exert multiple effects on the vascular endothelium. These include effects on nitric oxide (NO) and angiotensin II-mediated actions. Many BP lowering drugs can inhibit platelet activity, although the relevance of this property is unknown, especially if patients are also taking platelet inhibitors (e.g. aspirin). Antihypertensive drugs also influence Fibrinolysis and coagulation. These effects may be mediated by a variety of mechanisms, including altering insulin sensitivity. The haemostatic actions of anti hypertensive drugs deserve greater recognition and further investigation.
引用
收藏
页码:2445 / 2464
页数:20
相关论文
共 345 条
[31]   Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) [J].
Brown, MJ ;
Palmer, CR ;
Castaigne, A ;
de Leeuw, PW ;
Mancia, G ;
Rosenthal, T ;
Ruilope, LM .
LANCET, 2000, 356 (9227) :366-372
[32]   Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo [J].
Brown, NJ ;
Nakamura, S ;
Ma, LJ ;
Nakamura, I ;
Donnert, E ;
Freeman, M ;
Vaughan, DE ;
Fogo, AB .
KIDNEY INTERNATIONAL, 2000, 58 (03) :1219-1227
[33]   ACE inhibition versus angiotensin type 1 receptor antagonism - Differential effects on PAM over time [J].
Brown, NJ ;
Kumar, S ;
Painter, CA ;
Vaughan, DE .
HYPERTENSION, 2002, 40 (06) :859-865
[34]  
Buczko W, 2001, Med Sci Monit, V7, P600
[35]  
CAIMI G, 1983, JPN HEART J, V24, P723
[36]  
CAMPBELL DB, 1990, AM J CARDIOL, V65, pH11
[37]  
CASERLY IP, 2000, EXPERT OPIN PHARMACO, V1, P419
[38]  
Cattaneo M, 1997, THROMB HAEMOSTASIS, V77, P986
[39]  
CERRITO F, 1993, LIFE SCI, V53, P209
[40]   INHIBITION OF LOW-DENSITY OXIDATION IN-VITRO BY THE 6-HYDROXY-METABOLITES AND 7-HYDROXY-METABOLITES OF DOXAZOSIN, AN ALPHA(1)-ADRENERGIC ANTIHYPERTENSIVE AGENT [J].
CHAIT, A ;
GILMORE, M ;
KAWAMURA, A .
AMERICAN JOURNAL OF HYPERTENSION, 1994, 7 (02) :159-167